Article 6 governs the Part I scientific assessment (jointly assessed by the Member States concerned and led by the Reporting Member State): therapeutic and public-health relevance, design quality, risk-benefit balance, compliance with manufacturing/import provisions, compliance with labelling, completeness and adequacy of the investigator's brochure. Article 7 governs the Part II assessment (each Member State concerned individually): informed consent, recruitment arrangements, compensation, suitability of investigators/sites, damage compensation, data-protection rules, biological samples management, financial-flow disclosure.
The graph holds this control, the 0 it maps to, and the evidence behind each claim, over MCP and REST.